BioAxone is poised to revolutionize the way spinal cord injury is treated. The company is currently privately financed and has grown a strong pipeline from non-dilutive grant financing.
BioAxone is building on the following value:
– Experienced management
– Exceptional clinical results showing safety and efficacy of Cethrin™ for SCI treatment
– Validated science
– Over 14 issued patents (US and Global)
– Key partnerships to build the business
– Understanding of translational medicine to bring new drugs forward to clinical testing
– Successful NIH/SBIR funding and a strong pipeline
For more information on investments in Spinal Cord Injury, please visit Invest in Cures for SCI.
For direct information on investment opportunities, please contact:
Dr. Lisa McKerracher
Chief Executive Officer, BioAxone
(617) 401 3115